基于血液基因检测为指导的肺腺癌多学科精准治疗1例  

MDT precision therapy of lung adenocarcinoma under blood gene detection: A case report

作　　者：陈雪琴[1] 张仕蓉 江洪[1] 夏冰[1] 周健[1] 王利民[1] 马胜林[1] 

机构地区：[1]杭州市第一人民医院,杭州市肿瘤医院,南京医科大学附属杭州医院肺癌诊治中心,浙江杭州310006

出　　处：《实用肿瘤杂志》2016年第4期301-305,共5页Journal of Practical Oncology

基　　金：杭州市重大科技创新项目(20112313A01)

摘　　要：本文介绍1例肺腺癌患者多学科诊治过程。该病例因右侧肺部占位首诊,经多学科讨论后行手术治疗,术后病理证实为腺癌。6月后患者出现肝转移,基因检测提示表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变,经多学科讨论,给予酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)一线靶向治疗,此后疾病反复多次进展,在血液循环肿瘤DNA基因检测引导下,疾病得到控制并有较好的生活质量。此病例的诊疗过程说明,肺癌患者需要多学科诊治,基于血液基因检测,最终实现规范化的精准治疗。The history of multidisciplinary team（ MDT） treatment and diagnosis of a lung adenocarcinoma patient was described. This patient was diagnosed of right lung mass and received operation after MDT discussion,then adenocarcinnoma was comfirmed by pathology. Liver metastasis was presented after 6 months and tyrosine kinase inhibitor（ TKI） was administered as first therapy by terms of EGFR sensitive mutation. Although the disease recurred several times,it was still controlled and she had better quality of life on account of circulation tumor DNA gene detection. This case indicated that MDT discussion was key in lung cancer treatment. Guided by blood gene detection,the standard precision therapy was achieved.

关 键 词：肺肿瘤/药物疗法 肺肿瘤/病理学 肺肿瘤/治疗 肿瘤治疗方案 肿瘤分期 癌基因 基因 erbB-1 突变 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]